THROMBOLYTIC THERAPY

被引:11
作者
EISENBERG, MS
AGHABABIAN, RV
BOSSAERT, L
JAFFE, AS
ORNATO, JP
WEAVER, WD
机构
[1] University of Washington, Seattle
[2] University of Massachusetts, Worcester
[3] Washington University, St Louis, MO
[4] University of Virginia, Richmond
关键词
ACUTE MYOCARDIAL INFARCTION; THROMBOLYTIC THERAPY;
D O I
10.1016/S0196-0644(05)80473-1
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
All patients with symptoms and ECG findings suggestive of acute myocardial infarction (AMI) should be considered for treatment with thrombolytic agents. The decision to use thrombolytic therapy is a clinical judgment based upon a weighing of the potential benefits versus the possible risks. The physician must take into account relative contraindications, age of the patient, area of jeopardized myocardium, and duration of symptoms. Health professionals involved in the care of AMI patients should develop written plans and protocols addressing the following matters: identification of patients with chest pain in the prehospital setting (this applies to hospitals that receive patients from emergency medical services systems), triage of patients in the emergency department, obtaining the 12-lead electrocardiogram, determination of contraindications, authority for ordering thrombolytic therapy, and consultation for atypical cases. There also should be agreed standards for the time interval from arrival in the ED to administration of the thrombolytic agent, as well as a commitment to the prospective monitoring of procedures and times to assure continuous improvement. A time interval for treatment (arrival in ED to administration of drug) of 30 to 60 minutes should be achievable for patients who present with typical symptoms and ECG findings.
引用
收藏
页码:417 / 427
页数:11
相关论文
共 60 条
  • [1] ACC/AHA Task Force, Guidelines for the early management of patients with acute myocardial infarction, Journal of the American College of Cardiology, 16, pp. 249-292, (1990)
  • [2] Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction, Lancet, 1, pp. 397-402, (1986)
  • [3] Randomized trial of intravenous streptokinase oral aspirin both or neither among 17187 cases of suspected acute myocardial infarction ISIS-2, Lancet, 2, pp. 349-360, (1988)
  • [4] Wilcox, Olsson, Skene, Et al., Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction: Anglo-Scandinavian Study of Early Thrombolysis (ASSET), Lancet, 2, pp. 525-530, (1988)
  • [5] Effect of intravenous APSAC on mortality after acute myocardial infarction: Preliminary report of a placebo-controlled clinical trial, Lancet, 317, pp. 545-549, (1988)
  • [6] White, Norris, Brown, Et al., Effect of intravenous streptokinase on left ventricular function and early survival after acute myocardial infarction, N Engl J Med, 317, pp. 850-855, (1987)
  • [7] A prospective trial of intravenous streptokinase in acute myocardial infarction (ISAM) Mortality morbidity and infarct size at 21 days, New England Journal of Medicine, 314, pp. 1465-1471, (1986)
  • [8] Kennedy, Martin, David, Et al., The Western Washington Intravenous Streptokinase in Acute Myocardial Infarction randomized trial, Circulation, 77, pp. 345-352, (1988)
  • [9] Long-term effects of intravenous thrombolysis in acute myocardial infarction: Final report of the GISSI study, Lancet, 2, pp. 871-874, (1987)
  • [10] Koren, Weiss, Hasin, Et al., Prevention of myocardial damage in acute myocardial ischemia by early treatment with intravenous streptokinase, N Engl J Med, 313, pp. 1384-1389, (1985)